March 11, 2013
Mallinckrodt, the Pharmaceutical business of Covidien, has provided an update on the molybdenum-99 (Mo-99) supply outlook. Mallinckrodt’s supply situation has significantly improved and they are optimistic that the patient impact will be minimized during any potential concurrent shutdowns of the High Flux Reactor (unplanned) and National Research Universal reactor (long scheduled) in the coming weeks.
Through added resources, Mallinckrodt will be able to meet the majority of customer needs for technetium-99m (Tc-99m) generators in the coming months. The anticipated two-week period of slight reductions in the Tc-99m generator production is planned for April 14 to April 28.
Please see the attached customer letter for more information.